Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- A N.I.C.E. Development for Generex Oral-lyn in the U.K.
- R.J Steffens submits: The United Kingdom's National Institute for Health and Clinical Excellence (NICE) has recently begun the draft scope for the official Health Technology Appraisal of Generex's GNBT novel buccal insulin for the management of type 1 diabetes. Oral-lyn is not yet licensed for sale in the UK. Oral-lyn...
- External links 2009-10-18
- Oral-lyn vs. Afresa: How Generex Will Beat Mannkind
- R.J Steffens submits: As biotech companies and large pharma embark on paths to usher in more effective diabetes drugs to market, one of the more significant concerns regarding diabetes related drug development is safety. The FDA has increasingly issued new alerts from previously approved drugs such as GlaxoSmithKline's GSK Avandia,...
- External links 2009-11-19
Additional Resources
- Four Drug Companies Vying for Diabetes Patients
- R.J Steffens submits: The American Association of Diabetes Educators [AADE] released results last week at its high profile 35th Annual Meeting from an innovative new survey entitled the "Injection Impact Report". The report highlights the level of communication between patients and healthcare providers relating to insulin injections and...
- External links 2008-08-17
- Genentech and Generex: New HER2/neu Research
- R.J Steffens submits: This year's San Antonio Breast Cancer Symposium contained many studies that pertain to HER2/neu treatment. Current treatment revolves around Genentech's DNA Herceptin, but the event brings together many researchers who present their findings and a glimpse of improved future HER2/nue cancer treatment options. Large...
- External links 2008-12-15
- << Previous
- page 1 of 1
- Next >>
